BACKGROUND: No randomized trials have compared survival outcomes for men with localized prostate cancer (PC) being treated with radical prostatectomy (RP) or external beam radiotherapy (EBRT). The goal of the study, therefore, was to estimate the association of RP (compared with EBRT) with overall and PC mortality. METHODS: We analyzed an observational cohort from the population-based Prostate Cancer Outcomes Study, which included men aged 55 to 74 years diagnosed with localized PC between October 1994 and October 1995 who underwent either RP (n = 1164) or EBRT (n = 491) within 1 year of diagnosis. Patients were followed until death or study end (December 31, 2010). Overall and disease-specific mortality were assessed with multivariable survival analysis, with propensity scores to adjust for potential treatment selection confounders (demographics, comorbidities, and tumor characteristics). All statistical tests were two-sided. RESULTS: After 15 years of follow-up, there were 568 deaths, including 104 from PC. RP was associated with statistically significant advantages for overall (hazard ratio [HR] = 0.60, 95% confidence interval [CI] = 0.53 to 0.70, P <.0001.) and disease-specific mortality (HR = 0.35, 95% CI = 0.26 to 0.49, P <.0001.). Mortality benefits for RP were also observed within treatment propensity quintiles, when subjects were pair-matched on propensity scores, and in subgroup analyses based on age, tumor characteristics, and comorbidity. CONCLUSIONS: Population-based observational data on men diagnosed with localized PC in the mid-1990s suggest a mortality benefit associated with RP vs EBRT. Possible explanations include residual selection bias or a true survival advantage. Results might be less applicable for men facing treatment decisions today.
BACKGROUND: No randomized trials have compared survival outcomes for men with localized prostate cancer (PC) being treated with radical prostatectomy (RP) or external beam radiotherapy (EBRT). The goal of the study, therefore, was to estimate the association of RP (compared with EBRT) with overall and PC mortality. METHODS: We analyzed an observational cohort from the population-based Prostate Cancer Outcomes Study, which included men aged 55 to 74 years diagnosed with localized PC between October 1994 and October 1995 who underwent either RP (n = 1164) or EBRT (n = 491) within 1 year of diagnosis. Patients were followed until death or study end (December 31, 2010). Overall and disease-specific mortality were assessed with multivariable survival analysis, with propensity scores to adjust for potential treatment selection confounders (demographics, comorbidities, and tumor characteristics). All statistical tests were two-sided. RESULTS: After 15 years of follow-up, there were 568 deaths, including 104 from PC. RP was associated with statistically significant advantages for overall (hazard ratio [HR] = 0.60, 95% confidence interval [CI] = 0.53 to 0.70, P <.0001.) and disease-specific mortality (HR = 0.35, 95% CI = 0.26 to 0.49, P <.0001.). Mortality benefits for RP were also observed within treatment propensity quintiles, when subjects were pair-matched on propensity scores, and in subgroup analyses based on age, tumor characteristics, and comorbidity. CONCLUSIONS: Population-based observational data on men diagnosed with localized PC in the mid-1990s suggest a mortality benefit associated with RP vs EBRT. Possible explanations include residual selection bias or a true survival advantage. Results might be less applicable for men facing treatment decisions today.
Authors: Robert A Greevy; Carlos G Grijalva; Christianne L Roumie; Cole Beck; Adriana M Hung; Harvey J Murff; Xulei Liu; Marie R Griffin Journal: Pharmacoepidemiol Drug Saf Date: 2012-05 Impact factor: 2.890
Authors: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Dawn Stacey; Carol L Bennett; Michael J Barry; Nananda F Col; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; France Légaré; Richard Thomson Journal: Cochrane Database Syst Rev Date: 2011-10-05
Authors: Mark S Litwin; Sheldon Greenfield; Eric P Elkin; Deborah P Lubeck; Jeanette M Broering; Sherrie H Kaplan Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette Journal: N Engl J Med Date: 2009-06-11 Impact factor: 91.245
Authors: Pirus Ghadjar; Alberto Briganti; Peter J L De Visschere; Jurgen J Fütterer; Gianluca Giannarini; Hendrik Isbarn; Piet Ost; Prasanna Sooriakumaran; Christian I Surcel; Roderick C N van den Bergh; Inge M van Oort; Ofer Yossepowitch; Guillaume Ploussard Journal: World J Urol Date: 2014-07-05 Impact factor: 4.226
Authors: Richard M Hoffman; Mary Lo; Jack A Clark; Peter C Albertsen; Michael J Barry; Michael Goodman; David F Penson; Janet L Stanford; Antoinette M Stroup; Ann S Hamilton Journal: J Clin Oncol Date: 2017-05-11 Impact factor: 44.544
Authors: Ann S Hamilton; Steven T Fleming; Dian Wang; Michael Goodman; Xiao-Cheng Wu; Jean B Owen; Mary Lo; Alex Ho; Roger T Anderson; Trevor Thompson Journal: Am J Clin Oncol Date: 2016-02 Impact factor: 2.339
Authors: Philip V Barbosa; I-Chun Thomas; Sandy Srinivas; Mark K Buyyounouski; Benjamin I Chung; Glenn M Chertow; Steven M Asch; Todd H Wagner; James D Brooks; John T Leppert Journal: Eur Urol Date: 2016-03-02 Impact factor: 20.096
Authors: Morgan M Millar; Anita Y Kinney; Nicola J Camp; Lisa A Cannon-Albright; Mia Hashibe; David F Penson; Anne C Kirchhoff; Deborah W Neklason; Alicia W Gilsenan; Gretchen S Dieck; Antoinette M Stroup; Sandra L Edwards; Carrie Bateman; Marjorie E Carter; Carol Sweeney Journal: Am J Epidemiol Date: 2019-05-01 Impact factor: 4.897
Authors: Marta Barrado; Idoia Blanco-Luquin; Paola Andrea Navarrete; Ignacio Visus; David Guerrero-Setas; David Escors; Grazyna Kochan; Fernando Arias Journal: Rep Pract Oncol Radiother Date: 2019-02-22